Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner
Rate ePoster

Oral Delivery (Focus Group – OrD)

Oral delivery of engineered bacterial membrane vesicles to ameliorate inflammatory bowel diseases

Jinhan He – China, Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University
Introduction:

Gut probiotics have been reported to ameliorate gut disorders. However, the use of live bacteria raises stability and safety concerns. Here, we introduce a cell-free, gut-targeted strategy based on probiotic-derived outer membrane vesicles (OMVs), which are termed as PO. Briefly, OMVs are biomineralized with tannic acid (POT) and encapsulated within pH-responsive alginate microbeads, forming an engineered platform (POTA) that amplifies their anti-inflammatory and antioxidant activities while ensuring intestinal release. We demonstrate that POTA significantly alleviates intestinal barrier damage and inflammation in inflammatory bowel disease (IBD).

Learning Objectives:

  • Understand the significant therapeutic potential of OMVs derived from probiotics on IBD.
  • Understand that polyphenols-modified bacterial membrane vesicles show enhanced anti-inflammatory effects.
  • Understand that the pH-sensitive alginate microbeads achieve targeted intestinal drug release.